Clinical trial
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have…
NCT00424502 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00424502 |
|---|---|
| Title | A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a TNF-Blocker. |
| Official title | An Open-label Study to Evaluate the Effect of MabThera on Treatment Response in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Previous TNF Inhibition. |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | rituximab [MabThera/Rituxan], Methotrexate |
| Enrollment | 20 |
| Start date | Jan 1, 2007 |
| Primary completion | Oct 1, 2009 |
| Completion | Oct 1, 2009 |
| First posted | Jan 19, 2007 |
| Last update posted | May 9, 2016 |
| Countries | Hungary |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: